Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676251 | 1.00 | CA2 (0.62) | CA2LMNAALDH1A1HDAC6HDAC1 | |
| SCHEMBL4683611 | 0.91 | CA2 (0.55) | CA2LMNAALDH1A1HDAC6HDAC1 | |
| SCHEMBL4683608 | 0.91 | CA2 (0.55) | CA2LMNAALDH1A1HDAC6HDAC1 | |
| SCHEMBL8660662 | 0.90 | CA2 (0.60) | CA2LMNAALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL7333583 | 0.88 | CA2 (0.49) | CA2LMNAALDH1A1HDAC6HDAC1 | |
| SCHEMBL9421803 | 0.87 | CA2 (0.65) | CA2LMNAALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL9421805 | 0.87 | CA2 (0.65) | CA2LMNAALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL2760067 | 0.87 | CA2 (0.64) | CA2ALDH1A1CYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL4683895 | 0.87 | CA2 (0.67) | CA2LMNAALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL2736137 | 0.87 | CA2 (0.64) | CA2ALDH1A1CYP3A4SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0997459-B1 | Intermediates for preparing retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-0839798-B1 | Intermediates for preparating non-peptide retroviral protease inhibitors | ABBOTT LAB (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-0486948-B1 | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-0997459-A1 | Intermediates for preparing retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5990135-A | FOR TREATING A RETROVIRAL INFECTION SUCH AS HIV INFECTION; FOR EXAMPLE 5S-N-((2-PYRIDINYL)METHOXYCARBONYL)VALINYLAMINO-2-((N-3 -PYRIDINYL)METHOXYCARBONYL)AMINO-4S-HYDROXY-1,6-DIPHENYL-2-AZAHEXANE AND OTHER COMPOUNDS OF GIVEN FORMULA | ABBOTT LABORATORIES (US) | 1999-11-23 | — | — | US | disclosed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | disclosed |
| US-5807870-A | SIDE EFFECT REDUCTION | BIOMEGA BOEHRINGER INGELHEIM RESEARCH LTD. (CA) | 1998-09-15 | — | — | US | disclosed |
| EP-0402646-B1 | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 1998-07-22 | — | — | EP | disclosed |
| EP-0839798-A2 | Intermediates for preparating non-peptide retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5670675-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| CN-1096293-A | Replacement pipecolinic acid derivative as the hiv protease inhibitor | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1994-12-14 | — | — | CN | disclosed |
| US-5362912-A | Process for the preparation of a substituted diaminodiol | ABBOTT LABORATORIES (US) | 1994-11-08 | — | — | US | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| WO-1994019332-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-09-01 | — | — | WO | disclosed |
| WO-1993023361-A1 | PROCESS FOR THE PREPARATION OF A SUBSTITUTED DIAMINODIOL | ABBOTT LABORATORIES (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993018003-A1 | SUBSTITUED PIPECOLINIC ACID DERIVATIVES AS HIV PROTEASE INHIBITORS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | disclosed |
| EP-0560268-A1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
| US-5142056-A | Human immunodeficiency virus protease inhibitor | ABBOTT LABORATORIES (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |